Management of multidrug-resistant viruses in the immunocompromised host

British Journal of Haematology

Volumn 156, Issue 5, 2012, Pages 559-572

  Sellar, Rob S ^a,b   Peggs, Karl S ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Allogeneic transplant; Cytomegalovirus; Herpesvirus; Multidrug resistant virus

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; ACICLOVIR; AIC 246; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; BAY 57 1293; BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; BILS 179 BS; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; IMIQUIMOD; LEFLUNOMIDE; LETERMOVIR; NUCLEOSIDE ANALOG; PENCICLOVIR; PLACEBO; PNU 182171; PNU 183792; RESIQUIMOD; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VALACICLOVIR;

ANEMIA; ANTIVIRAL ACTIVITY; CONTINUOUS INFUSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELECTROLYTE DISTURBANCE; GENITAL HERPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOTHERAPY; INFECTION PREVENTION; LIVER FUNCTION TEST; LOW DRUG DOSE; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; T LYMPHOCYTE; VARICELLA ZOSTER VIRUS; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; HERPES SIMPLEX; HERPES ZOSTER; HERPESVIRIDAE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; SIMPLEXVIRUS;

EID: 84857034596     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08988.x     Document Type: Review

References (138)

1. Adjuik, M., Babiker, A., Garner, P., Olliaro, P., Taylor, W. & White, N. (2004) Artesunate combinations for treatment of malaria: meta-analysis. The Lancet, 363, 9-17.
2. Ahmed, A.M., Brantley, J.S., Madkan, V., Mendoza, N. & Tyring, S.K. (2007) Managing herpes zoster in immunocompromised patients. Herpes, 14, 32-36.
3. Anaissie, E.J., Kontoyiannis, D.P., O'Brien, S., Kantarjian, H., Robertson, L., Lerner, S. & Keating, M.J. (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Annals of Internal Medicine, 129, 559-566.
4. Anderson, H., Scarffe, J.H., Sutton, R.N., Hickmott, E., Brigden, D. & Burke, C. (1984) Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. British Journal of Cancer, 50, 45-49.
5. Andrei, G., Snoeck, R., De Clercq, E., Esnouf, R., Fiten, P. & Opdenakker, G. (2000) Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. Journal of General Virology, 81, 639-648.
6. Avery, R.K., Bolwell, B.J., Yen-Lieberman, B., Lurain, N., Waldman, W.J., Longworth, D.L., Taege, A.J., Mossad, S.B., Kohn, D., Long, J.R., Curtis, J., Kalaycio, M., Pohlman, B. & Williams, J.W. (2004) Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplantation, 34, 1071-1075.
7. Avery, R.K., Marty, F.M., Strasfeld, L., Lee, I., Arrieta, A., Chou, S., Tatarowicz, W. & Villano, S. (2010a) Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transplant Infectious Disease, 12, 489-496.
8. Avery, R.K., Mossad, S.B., Poggio, E., Lard, M., Budev, M., Bolwell, B., Waldman, W.J., Braun, W., Mawhorter, S.D., Fatica, R., Krishnamurthi, V., Young, J.B., Shrestha, R., Stephany, B., Lurain, N. & Yen-Lieberman, B. (2010b) Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation, 90, 419-426.
9. Bacon, T.H., Howard, B.A., Spender, L.C. & Boyd, M.R. (1996) Activity of penciclovir in antiviral assays against herpes simplex virus. Journal of Antimicrobial Chemotherapy, 37, 303-313.
10. Bacon, T.H., Levin, M.J., Leary, J.J., Sarisky, R.T. & Sutton, D. (2003) Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clinical Microbiology Reviews, 16, 114-128.
11. van der Beek, M.T., Berger, S.P., Vossen, A.C., van der Blij-de Brouwer, C.S., Press, R.R., de Fijter, J.W., Claas, E.C. & Kroes, A.C. (2010) Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation, 89, 320-326.
12. Bernstein, D.I., Spruance, S.L., Arora, S.S., Schroeder, J.L. & Meng, T.C. (2005) Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clinical Infectious Diseases, 41, 808-814.
13. Betz, U.A., Fischer, R., Kleymann, G., Hendrix, M. & Rubsamen-Waigmann, H. (2002) Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrobial Agents and Chemotherapy, 46, 1766-1772.
14. Bhorade, S.M., Lurain, N.S., Jordan, A., Leischner, J., Villanueva, J., Durazo, R., Creech, S., Vigneswaran, W.T. & Garrity, E.R. (2002) Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. Journal of Heart and Lung Transplantation, 21, 1274-1282.
15. Biron, K.K., Stanat, S.C., Sorrell, J.B., Fyfe, J.A., Keller, P.M., Lambe, C.U. & Nelson, D.J. (1985) Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proceedings of the National Academy of Sciences of the United States of America, 82, 2473-2477.
16. Biron, C.A., Byron, K.S. & Sullivan, J.L. (1989) Severe herpesvirus infections in an adolescent without natural killer cells. The New England Journal of Medicine, 320, 1731-1735.
17. Biron, K.K., Harvey, R.J., Chamberlain, S.C., Good, S.S., Smith, III, A.A., Davis, M.G., Talarico, C.L., Miller, W.H., Ferris, R., Dornsife, R.E., Stanat, S.C., Drach, J.C., Townsend, L.B. & Koszalka, G.W. (2002) Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrobial Agents and Chemotherapy, 46, 2365-2372.
18. Biswas, S., Kleymann, G., Swift, M., Tiley, L.S., Lyall, J., Aguirre-Hernandez, J. & Field, H.J. (2008a) A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target. Journal of Antimicrobial Chemotherapy, 61, 1044-1047.
19. Biswas, S., Tiley, L.S., Zimmermann, H., Birkmann, A. & Field, H.J. (2008b) Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity. Antiviral Research, 80, 81-85.
20. Blyth, E., Clancy, L., Simms, R., Gaundar, S., O'Connell, P., Micklethwaite, K. & Gottlieb, D.J. (2011) BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses. Transplantation, 92, 1077-1084.
21. Boeckh, M., Nichols, W.G., Papanicolaou, G., Rubin, R., Wingard, J.R. & Zaia, J. (2003a) Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biology of Blood and Marrow Transplantation, 9, 543-558.
22. Boeckh, M., Leisenring, W., Riddell, S.R., Bowden, R.A., Huang, M.L., Myerson, D., Stevens-Ayers, T., Flowers, M.E., Cunningham, T. & Corey, L. (2003b) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood, 101, 407-414.
23. Boeckh, M., Kim, H.W., Flowers, M.E., Meyers, J.D. & Bowden, R.A. (2006) Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation - a randomized double-blind placebo-controlled study. Blood, 107, 1800-1805.
24. Braithwaite, D.K. & Ito, J. (1993) Compilation, alignment, and phylogenetic relationships of DNA polymerases. Nucleic Acids Research, 21, 787-802.
25. Brideau, R.J., Knechtel, M.L., Huang, A., Vaillancourt, V.A., Vera, E.E., Oien, N.L., Hopkins, T.A., Wieber, J.L., Wilkinson, K.F., Rush, B.D., Schwende, F.J. & Wathen, M.W. (2002) Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Research, 54, 19-28.
26. Brink, A.A., van Gelder, M., Wolffs, P.F., Bruggeman, C.A. & van Loo, I.H. (2011) Compartmentalization of acyclovir-resistant varicella zoster virus: implications for sampling in molecular diagnostics. Clinical Infectious Diseases, 52, 982-987.
27. Broers, A.E., van Der Holt, R., van Esser, J.W., Gratama, J.W., Henzen-Logmans, S., Kuenen-Boumeester, V., Lowenberg, B. & Cornelissen, J.J. (2000) Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood, 95, 2240-2245.
28. Chakrabarti, S., Pillay, D., Ratcliffe, D., Cane, P.A., Collingham, K.E. & Milligan, D.W. (2000a) Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. Journal of Infectious Diseases, 181, 2055-2058.
29. Chakrabarti, S., Collingham, K.E., Fegan, C.D., Pillay, D. & Milligan, D.W. (2000b) Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy? Bone Marrow Transplantation, 26, 305-307.
30. Chen, Y., Scieux, C., Garrait, V., Socie, G., Rocha, V., Molina, J.M., Thouvenot, D., Morfin, F., Hocqueloux, L., Garderet, L., Esperou, H., Selimi, F., Devergie, A., Leleu, G., Aymard, M., Morinet, F., Gluckman, E. & Ribaud, P. (2000) Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clinical Infectious Diseases, 31, 927-935.
31. Ciesla, S.L., Trahan, J., Wan, W.B., Beadle, J.R., Aldern, K.A., Painter, G.R. & Hostetler, K.Y. (2003) Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Research, 59, 163-171.
32. Cobbold, M., Khan, N., Pourgheysari, B., Tauro, S., McDonald, D., Osman, H., Assenmacher, M., Billingham, L., Steward, C., Crawley, C., Olavarria, E., Goldman, J., Chakraverty, R., Mahendra, P., Craddock, C. & Moss, P.A. (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. The Journal of Experimental Medicine, 202, 379-386.
33. Coen, D.M., Kosz-Vnenchak, M., Jacobson, J.G., Leib, D.A., Bogard, C.L., Schaffer, P.A., Tyler, K.L. & Knipe, D.M. (1989) Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proceedings of the National Academy of Sciences of the United States of America, 86, 4736-4740.
34. Collins, P. & Ellis, M.N. (1993) Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. Journal of Medical Virology, (Suppl 1), 58-66.
35. Comoli, P., Basso, S., Azzi, A., Moretta, A., De Santis, R., Del Galdo, F., De Palma, R., Valente, U., Nocera, A., Perfumo, F., Locatelli, F., Maccario, R. & Ginevri, F. (2003) Dendritic cells pulsed with polyomavirus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. Journal of the American Society of Nephrology, 14, 3197-3204.
36. Cortelezzi, A., Pasquini, M.C., Gardellini, A., Gianelli, U., Bossi, A., Reda, G., Sarina, B., Musto, P., Barcellini, W., Neri, A. & Deliliers, G.L. (2009) Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia, 23, 2027-2033.
37. Crumpacker, C.S., Schnipper, L.E., Marlowe, S.I., Kowalsky, P.N., Hershey, B.J. & Levin, M.J. (1982) Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. The New England Journal of Medicine, 306, 343-346.
38. Crute, J.J., Grygon, C.A., Hargrave, K.D., Simoneau, B., Faucher, A.M., Bolger, G., Kibler, P., Liuzzi, M. & Cordingley, M.G. (2002) Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nature Medicine, 8, 386-391.
39. Dambrosi, S., Martin, M., Yim, K., Miles, B., Canas, J., Sergerie, Y. & Boivin, G. (2010) Neurovirulence and latency of drug-resistant clinical herpes simplex viruses in animal models. Journal of Medical Virology, 82, 1000-1006.
40. Duan, J., Liuzzi, M., Paris, W., Liard, F., Browne, A., Dansereau, N., Simoneau, B., Faucher, A.M. & Cordingley, M.G. (2003) Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1. Antimicrobial Agents and Chemotherapy, 47, 1798-1804.
41. Efferth, T., Dunstan, H., Sauerbrey, A., Miyachi, H. & Chitambar, C.R. (2001) The anti-malarial artesunate is also active against cancer. International Journal of Oncology, 18, 767-773.
42. Efferth, T., Marschall, M., Wang, X., Huong, S.M., Hauber, I., Olbrich, A., Kronschnabl, M., Stamminger, T. & Huang, E.S. (2002) Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. Journal of Molecular Medicine, 80, 233-242.
43. Efferth, T., Romero, M.R., Wolf, D.G., Stamminger, T., Marin, J.J. & Marschall, M. (2008) The antiviral activities of artemisinin and artesunate. Clinical Infectious Diseases, 47, 804-811.
44. Einsele, H., Roosnek, E., Rufer, N., Sinzger, C., Riegler, S., Loffler, J., Grigoleit, U., Moris, A., Rammensee, H.G., Kanz, L., Kleihauer, A., Frank, F., Jahn, G. & Hebart, H. (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood, 99, 3916-3922.
45. Einsele, H., Reusser, P., Bornhauser, M., Kalhs, P., Ehninger, G., Hebart, H., Chalandon, Y., Kroger, N., Hertenstein, B. & Rohde, F. (2006) Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood, 107, 3002-3008.
46. Elion, G.B. (1993) Acyclovir: discovery, mechanism of action, and selectivity. Journal of Medical Virology, (Suppl 1), 2-6.
47. Emery, V.C. & Griffiths, P.D. (2000) Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 97, 8039-8044.
48. Erice, A. (1999) Resistance of human cytomegalovirus to antiviral drugs. Clinical Microbiology Reviews, 12, 286-297.
49. Faulds, D. & Heel, R.C. (1990) Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs, 39, 597-638.
50. Feuchtinger, T., Matthes-Martin, S., Richard, C., Lion, T., Fuhrer, M., Hamprecht, K., Handgretinger, R., Peters, C., Schuster, F.R., Beck, R., Schumm, M., Lotfi, R., Jahn, G. & Lang, P. (2006) Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. British Journal of Haematology, 134, 64-76.
51. Feuchtinger, T., Richard, C., Joachim, S., Scheible, M.H., Schumm, M., Hamprecht, K., Martin, D., Jahn, G., Handgretinger, R. & Lang, P. (2008) Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. Journal of Immunotherapy, 31, 199-206.
52. Feuchtinger, T., Opherk, K., Bethge, W.A., Topp, M.S., Schuster, F.R., Weissinger, E.M., Mohty, M., Or, R., Maschan, M., Schumm, M., Hamprecht, K., Handgretinger, R., Lang, P. & Einsele, H. (2010) Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood, 116, 4360-4367.
53. Foulongne, V., Turriere, C., Diafouka, F., Abraham, B., Lastere, S. & Segondy, M. (2004) Ganciclovir resistance mutations in UL97 and UL54 genes of human cytomegalovirus isolates resistant to ganciclovir. Acta Virologica, 48, 51-55.
54. Gaudreau, A., Hill, E., Balfour, Jr, H.H., Erice, A. & Boivin, G. (1998) Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. Journal of Infectious Diseases, 178, 297-303.
55. Gerna, G., Lilleri, D., Zecca, M., Alessandrino, E.P., Baldanti, F., Revello, M.G. & Locatelli, F. (2005) Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica, 90, 526-533.
56. Gilbert, C., Roy, J., Belanger, R., Delage, R., Beliveau, C., Demers, C. & Boivin, G. (2001) Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrobial Agents and Chemotherapy, 45, 3669-3671.
57. Ginevri, F., Azzi, A., Hirsch, H.H., Basso, S., Fontana, I., Cioni, M., Bodaghi, S., Salotti, V., Rinieri, A., Botti, G., Perfumo, F., Locatelli, F. & Comoli, P. (2007) Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. American Journal of Transplantation, 7, 2727-2735.
58. Goldner, T., Hewlett, G., Ettischer, N., Ruebsamen-Schaeff, H., Zimmermann, H. & Lischka, P. (2011) The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. Journal of Virology, 85, 10884-10893.
59. Goodrich, J.M., Bowden, R.A., Fisher, L., Keller, C., Schoch, G. & Meyers, J.D. (1993) Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Annals of Internal Medicine, 118, 173-178.
60. Hanley, P.J., Cruz, C.R., Savoldo, B., Leen, A.M., Stanojevic, M., Khalil, M., Decker, W., Molldrem, J.J., Liu, H., Gee, A.P., Rooney, C.M., Heslop, H.E., Dotti, G., Brenner, M.K., Shpall, E.J. & Bollard, C.M. (2009) Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood, 114, 1958-1967.
61. Harkensee, C., Vasdev, N., Gennery, A.R., Willetts, I.E. & Taylor, C. (2008) Prevention and management of BK-virus associated haemorrhagic cystitis in children following haematopoietic stem cell transplantation - a systematic review and evidence-based guidance for clinical management. British Journal of Haematology, 142, 717-731.
62. Hartline, C.B., Harden, E.A., Williams-Aziz, S.L., Kushner, N.L., Brideau, R.J. & Kern, E.R. (2005) Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity. Antiviral Research, 65, 97-105.
63. Hatchette, T., Tipples, G.A., Peters, G., Alsuwaidi, A., Zhou, J. & Mailman, T.L. (2008) Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature. Pediatric Infectious Disease Journal, 27, 75-77.
64. Hromas, R., Cornetta, K., Srour, E., Blanke, C. & Broun, E.R. (1994) Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood, 84, 1689-1690.
65. Javaly, K., Wohlfeiler, M., Kalayjian, R., Klein, T., Bryson, Y., Grafford, K., Martin-Munley, S. & Hardy, W.D. (1999) Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. Journal of Acquired Immune Deficiency Syndromes, 21, 301-306.
66. Jedema, I., van de Meent, M., Pots, J., Kester, M.G., van der Beek, M.T. & Falkenburg, J.H. (2011) Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells. Haematologica, 96, 1204-1212.
67. John, G.T., Manivannan, J., Chandy, S., Peter, S., Fleming, D.H., Chandy, S.J., Balakrishnan, N., Krishnamurthy, K., Kirubakaran, M.G. & Jacob, C.K. (2005) A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplantation Proceedings, 37, 4303-4305.
68. Kaptein, S.J., Efferth, T., Leis, M., Rechter, S., Auerochs, S., Kalmer, M., Bruggeman, C.A., Vink, C., Stamminger, T. & Marschall, M. (2006) The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Research, 69, 60-69.
69. Kaul, D.R., Stoelben, S., Cober, E., Ojo, T., Sandusky, E., Lischka, P., Zimmermann, H. & Rubsamen-Schaeff, H. (2011) First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. American Journal of Transplantation, 11, 1079-1084.
70. Kim, J.H., Schaenman, J.M., Ho, D.Y. & Brown, J.M. (2011) Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients. Biology of Blood and Marrow Transplantation, 17, 259-264.
71. Klein, A., Miller, K.B., Sprague, K., DesJardin, J.A. & Snydman, D.R. (2011) A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT. Bone Marrow Transplantation, 46, 294-299.
72. Kleymann, G., Fischer, R., Betz, U.A., Hendrix, M., Bender, W., Schneider, U., Handke, G., Eckenberg, P., Hewlett, G., Pevzner, V., Baumeister, J., Weber, O., Henninger, K., Keldenich, J., Jensen, A., Kolb, J., Bach, U., Popp, A., Maben, J., Frappa, I., Haebich, D., Lockhoff, O. & Rubsamen-Waigmann, H. (2002) New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nature Medicine, 8, 392-398.
73. Koszalka, G.W., Johnson, N.W., Good, S.S., Boyd, L., Chamberlain, S.C., Townsend, L.B., Drach, J.C. & Biron, K.K. (2002) Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrobial Agents and Chemotherapy, 46, 2373-2380.
74. Krosky, P.M., Baek, M.C. & Coen, D.M. (2003) The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. Journal of Virology, 77, 905-914.
75. Lalezari, J.P., Stagg, R.J., Jaffe, H.S., Hitchcock, M.J. & Drew, W.L. (1996) A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC). Advances in Experimental Medicine and Biology, 394, 105-115.
76. Lau, P.K., Woods, M.L., Ratanjee, S.K. & John, G.T. (2011) Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clinical Infectious Diseases, 52, 279.
77. Leen, A.M., Myers, G.D., Sili, U., Huls, M.H., Weiss, H., Leung, K.S., Carrum, G., Krance, R.A., Chang, C.C., Molldrem, J.J., Gee, A.P., Brenner, M.K., Heslop, H.E., Rooney, C.M. & Bollard, C.M. (2006) Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nature Medicine, 12, 1160-1166.
78. Li, C.R., Greenberg, P.D., Gilbert, M.J., Goodrich, J.M. & Riddell, S.R. (1994) Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood, 83, 1971-1979.
79. Lischka, P., Hewlett, G., Wunberg, T., Baumeister, J., Paulsen, D., Goldner, T., Ruebsamen-Schaeff, H. & Zimmermann, H. (2010) In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrobial Agents and Chemotherapy, 54, 1290-1297.
80. Ljungman, P., Ellis, M.N., Hackman, R.C., Shepp, D.H. & Meyers, J.D. (1990) Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. Journal of Infectious Diseases, 162, 244-248.
81. Ljungman, P., de La Camara, R., Milpied, N., Volin, L., Russell, C.A., Crisp, A. & Webster, A. (2002) Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood, 99, 3050-3056.
82. Locksley, R.M., Flournoy, N., Sullivan, K.M. & Meyers, J.D. (1985) Infection with varicella-zoster virus after marrow transplantation. Journal of Infectious Diseases, 152, 1172-1181.
83. Marfori, J.E., Exner, M.M., Marousek, G.I., Chou, S. & Drew, W.L. (2007) Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. Journal of Clinical Virology, 38, 120-125.
84. Marty, F.M., Ljungman, P., Papanicolaou, G.A., Winston, D.J., Chemaly, R.F., Strasfeld, L., Young, J.A., Rodriguez, T., Maertens, J., Schmitt, M., Einsele, H., Ferrant, A., Lipton, J.H., Villano, S.A., Chen, H. & Boeckh, M. (2011) Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. The Lancet Infectious Diseases, 11, 284-292.
85. McSharry, J.J., McDonough, A., Olson, B., Talarico, C., Davis, M. & Biron, K.K. (2001) Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole l-riboside 1263W94. Clinical and Diagnostic Laboratory Immunology, 8, 1279-1281.
86. Meyers, J.D., Reed, E.C., Shepp, D.H., Thornquist, M., Dandliker, P.S., Vicary, C.A., Flournoy, N., Kirk, L.E., Kersey, J.H., Thomas, E.D. & Balfour, H.H. (1988) Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. The New England Journal of Medicine, 318, 70-75.
87. Micklethwaite, K.P., Clancy, L., Sandher, U., Hansen, A.M., Blyth, E., Antonenas, V., Sartor, M.M., Bradstock, K.F. & Gottlieb, D.J. (2008) Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood, 112, 3974-3981.
88. Miller, W.H. & Miller, R.L. (1980) Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. The Journal of Biological Chemistry, 255, 7204-7207.
89. Miller, W.H. & Miller, R.L. (1982) Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochemical Pharmacology, 31, 3879-3884.
90. Morfin, F. & Thouvenot, D. (2003) Herpes simplex virus resistance to antiviral drugs. Journal of Clinical Virology, 26, 29-37.
91. Morfin, F., Souillet, G., Bilger, K., Ooka, T., Aymard, M. & Thouvenot, D. (2000) Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. Journal of Infectious Diseases, 182, 290-293.
92. Naik, H.R., Siddique, N. & Chandrasekar, P.H. (1995) Foscarnet therapy for acyclovir-resistant herpes simplex virus 1 infection in allogeneic bone marrow transplant recipients. Clinical Infectious Diseases, 21, 1514-1515.
93. Nichols, W.G., Corey, L., Gooley, T., Drew, W.L., Miner, R., Huang, M., Davis, C. & Boeckh, M. (2001) Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood, 97, 867-874.
94. Oien, N.L., Brideau, R.J., Hopkins, T.A., Wieber, J.L., Knechtel, M.L., Shelly, J.A., Anstadt, R.A., Wells, P.A., Poorman, R.A., Huang, A., Vaillancourt, V.A., Clayton, T.L., Tucker, J.A. & Wathen, M.W. (2002) Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrobial Agents and Chemotherapy, 46, 724-730.
95. Olivo, P.D., Nelson, N.J. & Challberg, M.D. (1989) Herpes simplex virus type 1 gene products required for DNA replication: identification and overexpression. Journal of Virology, 63, 196-204.
96. Paolino, K., Sande, J., Perez, E., Loechelt, B., Jantausch, B., Painter, W., Anderson, M., Tippin, T., Lanier, E.R., Fry, T. & DeBiasi, R.L. (2011) Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001. Journal of Clinical Virology, 50, 167-170.
97. Park, K.D., Marti, L., Kurtzberg, J. & Szabolcs, P. (2006) In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood, 108, 1770-1773.
98. Peggs, K.S. (2009) Adoptive T cell immunotherapy for cytomegalovirus. Expert Opinion on Biological Therapy, 9, 725-736.
99. Peggs, K.S., Verfuerth, S., Pizzey, A., Khan, N., Guiver, M., Moss, P.A. & Mackinnon, S. (2003) Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. The Lancet, 362, 1375-1377.
100. Peggs, K.S., Verfuerth, S., Pizzey, A., Chow, S.L., Thomson, K. & Mackinnon, S. (2009) Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clinical Infectious Diseases, 49, 1851-1860.
101. Peggs, K.S., Thomson, K., Samuel, E., Dyer, G., Armoogum, J., Chakraverty, R., Pang, K., Mackinnon, S. & Lowdell, M.W. (2011) Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clinical Infectious Diseases, 52, 49-57.
102. Perry, C.M. & Faulds, D. (1996) Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs, 52, 754-772.
103. Prentice, H.G., Gluckman, E., Powles, R.L., Ljungman, P., Milpied, N.J., Camara, R., Mandelli, F., Kho, P., Kennedy, L. & Bell, A.R. (1997) Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Bone Marrow Transplantation, 19, 129-133.
104. Prichard, M.N. (2009) Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Reviews in Medical Virology, 19, 215-229.
105. Prichard, M.N., Kern, E.R., Hartline, C.B., Lanier, E.R. & Quenelle, D.C. (2011) CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections. Antimicrobial Agents and Chemotherapy, 55, 4728-4734.
106. Quenelle, D.C., Lampert, B., Collins, D.J., Rice, T.L., Painter, G.R. & Kern, E.R. (2010) Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. Journal of Infectious Diseases, 202, 1492-1499.
107. Reardon, J.E. & Spector, T. (1989) Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. The Journal of Biological Chemistry, 264, 7405-7411.
108. Reddehase, M.J., Weiland, F., Munch, K., Jonjic, S., Luske, A. & Koszinowski, U.H. (1985) Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. Journal of Virology, 55, 264-273.
109. Reusser, P., Cordonnier, C., Einsele, H., Engelhard, D., Link, D., Locasciulli, A. & Ljungman, P. (1996) European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 17, 813-817.
110. Reusser, P., Einsele, H., Lee, J., Volin, L., Rovira, M., Engelhard, D., Finke, J., Cordonnier, C., Link, H. & Ljungman, P. (2002) Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood, 99, 1159-1164.
111. Rinaldo, C.H., Gosert, R., Bernhoff, E., Finstad, S. & Hirsch, H.H. (2010) 1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrobial Agents and Chemotherapy, 54, 4714-4722.
112. Rogers, J.E., Cumpston, A., Newton, M. & Craig, M. (2011) Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. Transplant Infectious Disease, 13, 480-484.
113. Rooney, C.M., Smith, C.A., Ng, C.Y., Loftin, S.K., Sixbey, J.W., Gan, Y., Srivastava, D.K., Bowman, L.C., Krance, R.A., Brenner, M.K. & Heslop, H.E. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92, 1549-1555.
114. Sacks, S.L., Shafran, S.D., Diaz-Mitoma, F., Trottier, S., Sibbald, R.G., Hughes, A., Safrin, S., Rudy, J., McGuire, B. & Jaffe, H.S. (1998) A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Antimicrobial Agents and Chemotherapy, 42, 2996-2999.
115. Safrin, S., Crumpacker, C., Chatis, P., Davis, R., Hafner, R., Rush, J., Kessler, H.A., Landry, B. & Mills, J. (1991) A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. The New England Journal of Medicine, 325, 551-555.
116. Saral, R., Burns, W.H., Laskin, O.L., Santos, G.W. & Lietman, P.S. (1981) Acyclovir prophylaxis of herpes-simplex-virus infections. The New England Journal of Medicine, 305, 63-67.
117. Sauerbrei, A., Taut, J., Zell, R. & Wutzler, P. (2011) Resistance testing of clinical varicella-zoster virus strains. Antiviral Research, 90, 242-247.
118. Schiffer, J.T., Abu-Raddad, L., Mark, K.E., Zhu, J., Selke, S., Koelle, D.M., Wald, A. & Corey, L. (2010) Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proceedings of the National Academy of Sciences of the United States of America, 107, 18973-18978.
119. Schmit, I. & Boivin, G. (1999) Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed. Journal of Infectious Diseases, 180, 487-490.
120. Schnute, M.E., Cudahy, M.M., Brideau, R.J., Homa, F.L., Hopkins, T.A., Knechtel, M.L., Oien, N.L., Pitts, T.W., Poorman, R.A., Wathen, M.W. & Wieber, J.L. (2005) 4-Oxo-4, 7-dihydrothieno[2, 3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases. Journal of Medicinal Chemistry, 48, 5794-5804.
121. Scott, G.M., Weinberg, A., Rawlinson, W.D. & Chou, S. (2007) Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrobial Agents and Chemotherapy, 51, 89-94.
122. Shapira, M.Y., Resnick, I.B., Chou, S., Neumann, A.U., Lurain, N.S., Stamminger, T., Caplan, O., Saleh, N., Efferth, T., Marschall, M. & Wolf, D.G. (2008) Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clinical Infectious Diseases, 46, 1455-1457.
123. Steer, C.B., Szer, J., Sasadeusz, J., Matthews, J.P., Beresford, J.A. & Grigg, A. (2000) Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplantation, 25, 657-664.
124. Strasfeld, L., Lee, I., Tatarowicz, W., Villano, S. & Chou, S. (2010) Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. Journal of Infectious Diseases, 202, 104-108.
125. Sullivan, V., Talarico, C.L., Stanat, S.C., Davis, M., Coen, D.M. & Biron, K.K. (1992) A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature, 358, 162-164.
126. Thomson, K.J., Hart, D.P., Banerjee, L., Ward, K.N., Peggs, K.S. & Mackinnon, S. (2005) The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplantation, 35, 1065-1069.
127. Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J.R., Young, J.A. & Boeckh, M.J. (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biology of Blood and Marrow Transplantation, 15, 1143-1238.
128. Utzinger, J., Xiao, S.H., Tanner, M. & Keiser, J. (2007) Artemisinins for schistosomiasis and beyond. Current Opinion in Investigational Drugs, 8, 105-116.
129. Visse, B., Huraux, J.M. & Fillet, A.M. (1999) Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. Journal of Medical Virology, 59, 84-90.
130. Walter, E.A., Greenberg, P.D., Gilbert, M.J., Finch, R.J., Watanabe, K.S., Thomas, E.D. & Riddell, S.R. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. The New England Journal of Medicine, 333, 1038-1044.
131. Wan, W.B., Beadle, J.R., Hartline, C., Kern, E.R., Ciesla, S.L., Valiaeva, N. & Hostetler, K.Y. (2005) Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrobial Agents and Chemotherapy, 49, 656-662.
132. Wang, L.H., Peck, R.W., Yin, Y., Allanson, J., Wiggs, R. & Wire, M.B. (2003) Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrobial Agents and Chemotherapy, 47, 1334-1342.
133. Whitley, R.J., Kimberlin, D.W. & Roizman, B. (1998) Herpes simplex viruses. Clinical Infectious Diseases, 26, 541-553.
134. Winston, D.J., Young, J.A., Pullarkat, V., Papanicolaou, G.A., Vij, R., Vance, E., Alangaden, G.J., Chemaly, R.F., Petersen, F., Chao, N., Klein, J., Sprague, K., Villano, S.A. & Boeckh, M. (2008) Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood, 111, 5403-5410.
135. Wolf, D.G., Shimoni, A., Resnick, I.B., Stamminger, T., Neumann, A.U., Chou, S., Efferth, T., Caplan, O., Rose, J., Nagler, A. & Marschall, M. (2011) Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Research, 90, 183-186.
136. Wu, C.A., Nelson, N.J., McGeoch, D.J. & Challberg, M.D. (1988) Identification of herpes simplex virus type 1 genes required for origin-dependent DNA synthesis. Journal of Virology, 62, 435-443.
137. Wyles, D.L., Patel, A., Madinger, N., Bessesen, M., Krause, P.R. & Weinberg, A. (2005) Development of herpes simplex virus disease in patients who are receiving cidofovir. Clinical Infectious Diseases, 41, 676-680.
138. Xiong, X., Smith, J.L. & Chen, M.S. (1997) Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrobial Agents and Chemotherapy, 41, 594-599.